Theravance Biopharma, Inc.

Ladies and gentlemen, thank you for standing by. Good afternoon. I'd like to welcome everyone to the TheraFerence Biopharma second quarter 2021 conference call. During the presentation, all participants are in a listen-only mode. A question and answer session will follow the company's formal remarks. To question, please press star followed by the digit 1 on your telephone. Again, that's star 1 to ask a question. If listening via webcast, please mute the audio on your webcast device before asking a question over the phone. I will repeat these instructions after management completes their prepared remarks. Also, today's conference call is being recorded. And now I'd like to turn the call over to Gail Cohen, Vice President, Corporate Communications. Please go ahead.

Good afternoon, and thank you for joining the Theravance Biopharma second quarter 2021 conference call to discuss our business. As always, I remind you that this call will contain forward-looking statements that involve risks and uncertainties, including statements about our development pipeline, expected benefits of our products, anticipated timing of clinical trials, regulatory filings, and expected financial results. Information concerning factors that could cause results to differ materially from our forward-looking statements is described further in our filings with the SEC. Now, I would direct your attention to slide three. Joining us are Rick Winningham, Chief Executive Officer, followed by Rick Graham, Senior Vice President Development, Frank Pascalone, Chief Business Officer, and Andrew Hyman, Chief Financial Officer.

now i will hand the call to rick winningham for opening remarks thanks gail 2021 has been about progress progress of our clinical pipeline of our commercial asset upelry and progress as we as a company adapt to the ever-changing pandemic and define what our business will look like in the future i'm grateful to the team at theravance biopharma who continue to show resilience and perseverance while continuing to ensure our advancement and commitment to developing medicines to make a difference. Starting on slide five in the second quarter, we made strong progress delivering the data of one of our four pipeline catalysts, phase two data for Nezolcetinib, our investigational inhaled lung selective PANJAC inhibitor for acute and chronic lung injury. We continue to drive forward our clinical programs, preparing for two critical data readouts, Isoncetinib phase two B data in ulcerative colitis, which will report top-line results just ahead of ampryloxetine Phase III data for symptomatic neurogenic orthostatic hypotension in the third quarter. On the respiratory front, moving to slide six, you, Pelry, and Trilogy have continued to make strides, showing signs of rebounding from the pandemic headwinds of 2020 with continued market share and net sales growth. Frank will expand on the metrics from the second quarter and trends that we are continuing to see in July of 2021. We're also planning for a future of upelry as we, along with our partner, Beatrice, are initiating phase four clinical study. This study will compare improvements in lung function in adults with severe to very severe COPD and suboptimal inspiratory flow rate following once daily treatment with either upelry delivered via standard jet nebulizer or teatropium delivered via dry powder inhaler. Findings from this study are intended to provide data to support a possible label update and help better inform physicians as they are working with their patients to design COPD treatment plans. We expect the study to kick off later this year. I'll now turn the call over to Rick Bram, who will discuss the upcoming pipeline catalyst. Rick?